DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Chronic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Fibromyalgia (US)

Chronic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Fibromyalgia (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Fibromyalgia is a difficult disease to treat due to patient heterogeneity, frequent comorbid conditions, and a variety of symptoms including pain, depression, fatigue, and sleep dysfunction. The few drugs that are formally approved for the treatment of fibromyalgia (Pfizer’s Lyrica, Pierre Fabre’s/Allergan’s Savella, duloxetine) have limited efficacy, resulting in off-label use of a variety of antidepressants, analgesics, muscle relaxants, and sleep aids to manage patient symptoms. Although the recognition, diagnosis, and treatment of fibromyalgia has improved dramatically over the past decade, the treatment journeys of fibromyalgia patients are highly complex, with high rates of treatment discontinuation, drug-switching, and polypharmacy.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed fibromyalgia patients? What are the quarterly trends in prescribing among recently-treated and newly diagnosed fibromyalgia patients?
  • How has duloxetine been integrated into the treatment algorithm since losing market exclusivity? How has its generic availability affected other therapies?
  • What proportion of fibromyalgia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of fibromyalgia patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with fibromyalgia?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Pfizer, Allergan, Pierre-Fabre

Key drugs:  Lyrica, Savella, duloxetine, gabapentin, SNRIs, SSRIs, muscle relaxants, NSAIDs, opioid analgesics, sedative hypnotics, and others

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Fibromyalgia (US)
    • 2018 Treatment Algorithms: Claims Data Analysis in Fibromyalgia (November 2018)

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Natalie Taylor, PhD
  • Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Purchase Report

Recent reports:
You may also be interested in: